{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:06:52Z","timestamp":1741666012667,"version":"3.38.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejca.2025.115304","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T23:51:45Z","timestamp":1739663505000},"page":"115304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-7001","authenticated-orcid":false,"given":"Kosei","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-630X","authenticated-orcid":false,"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokuni","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurina","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-3840","authenticated-orcid":false,"given":"Akira","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kamio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-8253","authenticated-orcid":false,"given":"Kazuyoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-3338","authenticated-orcid":false,"given":"Kazuhiro","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115304_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2025.115304_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.3390\/cancers14122913","article-title":"Review of the standard and advanced screening, staging systems and treatment modalities for cervical cancer","volume":"14","author":"Boon","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"_4","key":"10.1016\/j.ejca.2025.115304_bib3","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","article-title":"Cervical cancer. version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Koh","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2025.115304_bib5","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/IGC.0b013e3181a58d3f","article-title":"Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent","volume":"19","author":"Narayan","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejca.2025.115304_bib7","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Due\u00f1as-Gonz\u00e1lez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12032-007-9023-1","article-title":"UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma","volume":"25","author":"Nagai","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014059528046","article-title":"Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor","volume":"4","author":"Basaki","year":"2001","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejca.2025.115304_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib13","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2025.115304_bib14","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115304_bib15","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1535-7163.MCT-09-0583","article-title":"Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models","volume":"8","author":"Daenen","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2025.115304_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115304_bib17","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2005.02.158","article-title":"Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials","volume":"23","author":"Noguchi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000067763","article-title":"Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer","volume":"64","author":"Kasumi","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2025.115304_bib19","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/bjs.5996","article-title":"Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer","volume":"94","author":"Nakajima","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2025.115304_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jjco\/hyl014","article-title":"Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial","volume":"36","author":"Akasu","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib21","first-page":"900","article-title":"Phase II study of UFT in cancer of the uterine cervix","volume":"12","author":"Noda","year":"1985","journal-title":"Gan Kagaku Ryoho"},{"key":"10.1016\/j.ejca.2025.115304_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2005.11.006","article-title":"Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better","volume":"101","author":"Noda","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib23","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1200\/JCO.2006.09.4532","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Rose","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib24","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"issue":"ement 2","key":"10.1016\/j.ejca.2025.115304_bib25","doi-asserted-by":"crossref","first-page":"S1276","DOI":"10.1016\/j.annonc.2023.10.028","article-title":"LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial","volume":"34","author":"McCormack","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115304_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115304_bib27","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115304_bib28","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115304_bib29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115304_bib30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115304_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.23.00954","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:06:35Z","timestamp":1741597595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"alternative-id":["S0959804925000851"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115304","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115304"}}